Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

Its kind of amazing how much information they have on the patients in the Kevetrin trial. The 59 year old women for example going for walks with her family, feeling better, by dose 2 stable spleen lesion but concern for a rising CA. This level of information I assume is known for all ~39 patients that are or have been in the trial. Makes an investor realize how little we know.

I will say this though if management says that Kevetrin is performing as expected..WOW! One need only go back to the preclinical work. They didn't overplay Brilacidin ABSSSI top line data which IMO came in over expectations so now consider that scenario for Kevetrin.